马兜铃酸肝脏致癌性争议及药物安全性思考
Shu Zhen Chen;Ya Ping Dong;Wen Wen;红阳 王
2021-1 Academic Journal of Second Military Medical University
0
被引量Recurrently deregulated lncRNAs in hepatocellular carcinoma
Yang Yang;Lei Chen;Jin Gu;Hanshuo Zhang;Jiapei Yuan;Qiuyu Lian;Guishuai Lv;Siqi Wang;Yang Wu;Yu Cheng T. Yang;Dongfang Wang;Yang Liu;Jing Tang;Guijuan Luo;Yang Li;Long Hu;Xinbao Sun;Dong Wang;Mingzhou Guo;乔然 郗;建忠 席;红阳 王;Michael Q. Zhang;Zhi John Lu
2017-2-13 Nature Communications
0
被引量The role of NAFLD in extrahepatic malignancies
Bo Zheng;Yan Jing Zhu;红阳 王;Lei Chen
2018-5 Journal of Hepatology
0
被引量Reversible transition between hepatocytes and liver progenitors for in vitro hepatocyte expansion
Han Wu;Xu Zhou;Gong Bo Fu;Zhi Ying He;Hong Ping Wu;Pu You;Charles Ashton;Xin Wang;红阳 王;He Xin Yan
2017-5-1 Cell Research
0
被引量Suppression of established hepatocarcinoma in adjuvant only immunotherapy
Bo Wang;Xuanyi Wang;玉梅 闻;Jing Fu;红阳 王;Zhangmei Ma;Yan Shi;Bin Wang
2015-12-9 Scientific Reports
0
被引量DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats
H. X. Yan;H. P. Wu;H. L. Zhang;C. Ashton;C. Tong;J. Wu;Q. J. Qian;红阳 王;Q. L. Ying
2013-9-19 Oncogene
0
被引量Precision diagnosis and treatment of liver cancer in China
Jing Fu;红阳 王
2018-1-1 Cancer Letters
0
被引量Cancer Letters special issue hepatobiliary cancer featuring the guest editor
红阳 王
2016-9-1 Cancer Letters
0
被引量Targeted therapy for hepatocellular carcinoma
Shuzhen Chen;Qiqi Cao;Wen Wen;红阳 王
2019-9-28 Cancer Letters
0
被引量Ψ-Bufarenogin, a lead compound of anti-cancer drug
Jin Ding;红阳 王
2015 Cell Cycle
0
被引量